MCID: GST040
MIFTS: 60

Gastric Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

MalaCards integrated aliases for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 14 69
Adenocarcinoma of Stomach 12
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 51

Classifications:



External Ids:

Disease Ontology 12 DOID:3717
NCIt 46 C4004
SNOMED-CT 64 408647009
UMLS 69 C0278701

Summaries for Gastric Adenocarcinoma

Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric signet ring cell adenocarcinoma and adenocarcinoma, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and PI3K-Akt signaling pathway. The drugs Taxotere and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 Stomach cancer, also known as gastric cancer, is cancer developing from the lining of the stomach. Early... more...

Related Diseases for Gastric Adenocarcinoma

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 279)
# Related Disease Score Top Affiliating Genes
1 gastric signet ring cell adenocarcinoma 32.5 CDH1 CDX2 CEACAM5
2 adenocarcinoma 31.8 CDH1 CTNNB1 ERBB2 HRAS MLH1 PTGS2
3 gastritis 30.8 CCKBR CDX2 CHGA GAST PTGS2 S100A8
4 squamous cell carcinoma 30.6 CDH1 CEACAM5 ERBB2 FHIT HRAS PTGS2
5 familial adenomatous polyposis 30.6 CDH1 CTNNB1 MLH1 MYC PTGS2
6 atrophic gastritis 30.6 CDX2 CHGA GAST S100A8
7 peptic ulcer disease 30.6 GAST PTGS2 S100A8
8 linitis plastica 30.4 CDH1 KRT20
9 mucoepidermoid carcinoma 30.2 CEACAM5 CHGA ERBB2
10 gastric ulcer 30.2 GAST PTGS2 TFF1
11 pancreatic ductal adenocarcinoma 30.2 CDH1 CTNNB1 ERBB2 HRAS
12 colon adenocarcinoma 30.1 CDH1 CEACAM5 CTNNB1 KRT20 MLH1 PTGS2
13 colorectal adenocarcinoma 29.7 CDH1 CDX2 CEACAM5 CTNNB1 HRAS KRT20
14 hepatocellular carcinoma 29.4 AFP CDH1 CEACAM5 CTNNB1 HRAS MYC
15 gastric cancer 29.1 AFP CCKBR CDH1 CDX2 CEACAM5 CTNNB1
16 lung cancer 28.9 CDH1 CEACAM5 CHGA CTNNB1 ERBB2 FHIT
17 gastric adenocarcinoma and proximal polyposis of the stomach 12.1
18 gastric cardia adenocarcinoma 11.4
19 gastric cancer, hereditary diffuse 11.2
20 krukenberg carcinoma 11.0
21 gastric papillary adenocarcinoma 11.0
22 gastric tubular adenocarcinoma 11.0
23 mucinous stomach adenocarcinoma 11.0
24 autoimmune atrophic gastritis 10.7 CHGA GAST
25 lobular neoplasia 10.7 CDH1 CTNNB1 ERBB2
26 vulva basal cell carcinoma 10.7 ERBB2 MYC
27 breast squamous cell carcinoma 10.7 CDH1 CEACAM5 ERBB2
28 gallbladder squamous cell carcinoma 10.7 CEACAM5 ERBB2
29 esophagus adenocarcinoma 10.7 CDX2 ERBB2 PTGS2
30 large intestine adenocarcinoma 10.7 CDH1 CTNNB1 KRT20
31 vulval paget's disease 10.7 CEACAM5 ERBB2 KRT20
32 breast metaplastic carcinoma 10.7 CDH1 CEACAM5 ERBB2
33 barrett's adenocarcinoma 10.7 ERBB2 FHIT PTGS2
34 papillary adenocarcinoma 10.7 CDH1 CEACAM5 ERBB2
35 mucinous ovarian cystadenoma 10.7 CDX2 CEACAM5 GAST
36 gastric diffuse adenocarcinoma 10.7 CDH1 CDX2 KRT20
37 female urethral cancer 10.7 CEACAM5 CHGA
38 breast cystic hypersecretory carcinoma 10.7 CDH1 ERBB2
39 esophageal disease 10.7 CDX2 GAST PTGS2
40 peptic ulcer perforation 10.7 GAST PTGS2 S100A8
41 nonseminomatous germ cell tumor 10.7 AFP ERBB2
42 infiltrative basal cell carcinoma 10.7 CDH1 CEACAM5 KRT20
43 small intestinal adenocarcinoma 10.7 CDX2 CTNNB1 ERBB2
44 adult teratoma 10.7 AFP CHGA
45 esophageal adenosquamous carcinoma 10.7 CDH1 CEACAM5
46 mucinous cystadenofibroma 10.7 AFP CEACAM5
47 ductal carcinoma in situ 10.7 CDH1 ERBB2 PTGS2
48 thymus adenocarcinoma 10.7 CDX2 CEACAM5 KRT20
49 gastrointestinal neuroendocrine benign tumor 10.7 CHGA GAST
50 vaginal benign neoplasm 10.7 CDX2 CHGA KRT20

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

GenomeRNAi Phenotypes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.5 HRAS
2 Decreased viability GR00221-A-1 9.5 CDH1 HRAS MYC RAF1 ROS1
3 Decreased viability GR00221-A-2 9.5 HRAS RAF1 ROS1
4 Decreased viability GR00221-A-3 9.5 HRAS MYC
5 Decreased viability GR00231-A 9.5 RAF1
6 Decreased viability GR00301-A 9.5 CDH1 RAF1
7 Decreased viability GR00342-S-1 9.5 ROS1

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.31 TFF1 PTGS2 CDX2 ERBB2 CCKBR CDH1
2 homeostasis/metabolism MP:0005376 10.31 TFF1 PTGS2 RAF1 CDX2 ERBB2 AFP
3 endocrine/exocrine gland MP:0005379 10.3 PTGS2 RAF1 CDX2 ERBB2 AFP CHGA
4 cardiovascular system MP:0005385 10.25 PTGS2 RAF1 CDH1 CTNNB1 CDX2 CHGA
5 growth/size/body region MP:0005378 10.21 TFF1 PTGS2 RAF1 CDH1 CTNNB1 CDX2
6 mortality/aging MP:0010768 10.2 PTGS2 RAF1 S100A8 CDH1 CTNNB1 CDX2
7 integument MP:0010771 10.11 PTGS2 RAF1 CDH1 CTNNB1 CCKBR FHIT
8 neoplasm MP:0002006 10.1 TFF1 RAF1 CDX2 ERBB2 AFP CDH1
9 embryo MP:0005380 10.08 S100A8 PTGS2 RAF1 CDH1 CTNNB1 CDX2
10 no phenotypic analysis MP:0003012 9.76 PTGS2 RAF1 ROS1 CDH1 CTNNB1 CHGA
11 normal MP:0002873 9.61 PTGS2 RAF1 CDH1 CTNNB1 CDX2 ERBB2
12 reproductive system MP:0005389 9.32 PTGS2 ROS1 CDH1 CTNNB1 CDX2 AFP

Drugs & Therapeutics for Gastric Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Taxotere 17 45 DOCETAXEL Rhone Poulenc Rorer May 1996

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Levoleucovorin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68538-85-2
4
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
5
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
6
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
7
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
8
Iron Approved Phase 4 7439-89-6 23925
9
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
10
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
11
Camptothecin Experimental Phase 4,Phase 2,Phase 1 7689-03-4
12 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
13 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
14 Antidotes Phase 4,Phase 3,Phase 2,Phase 1
15 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
16 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
17 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
18 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1
22 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
24 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
25 Antacids Phase 4,Phase 1
26 Anti-Ulcer Agents Phase 4,Phase 1
27 Gastrointestinal Agents Phase 4,Phase 1
28 Proton pump inhibitors Phase 4
29 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
30 Ferric Compounds Phase 4
31 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
32 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
33
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
34
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
35
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
36
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
37
Pancrelipase Approved, Investigational Phase 3,Phase 2,Phase 1 53608-75-6
38
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
39
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
40
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
41
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
42
Floxuridine Approved Phase 3,Phase 2 50-91-9 5790
43
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
44
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
45
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
46
Vinblastine Approved Phase 2, Phase 3 865-21-4 241903 13342
47
Pertuzumab Approved Phase 2, Phase 3 380610-27-5, 145040-37-5 2540
48
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
49
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
50 Racepinephrine Approved Phase 3 329-65-7

Interventional clinical trials:

(show top 50) (show all 349)

# Name Status NCT ID Phase Drugs
1 Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection Completed NCT00844675 Phase 4 rabeprazole;placebo
2 Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer Recruiting NCT02426034 Phase 4 Apatinib
3 Iron Replacement in Oesophagogastric Neoplasia Recruiting NCT01927328 Phase 4 Iron isomaltoside 1000
4 Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
5 Pharmacokinetic Study of Capecitabine After Total Gastrectomy for Stomach Adenocarcinoma Terminated NCT00871273 Phase 4 capecitabine
6 A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer Terminated NCT01260194 Phase 4 trastuzumab [Herceptin]
7 Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Unknown status NCT01015339 Phase 3 Paclitaxel;capecitabine;capecitabine;cisplatin
8 Taxanes or Platinum in Combination With Capecitabine Followed by Capecitabine Alone as First Line Treatment for Patients With Advanced Adenocarcinoma of Stomach or Esophagogastric Junction Unknown status NCT01468389 Phase 3 Capecitabine;capecitabine
9 SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer Unknown status NCT01583361 Phase 3 Oxaliplatin+S-1;Adjuvant Oxaliplatin/S-1(SOX)
10 Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer Unknown status NCT01283217 Phase 3 DS;SP
11 Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer Unknown status NCT02537171 Phase 3 apatinib
12 Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002883 Phase 3 cisplatin;fluorouracil
13 Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Completed NCT01640782 Phase 3 Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin;Leucovorin, 5-Fluorouracil
14 A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma Completed NCT01170663 Phase 3 Placebo;Paclitaxel
15 Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma Completed NCT00323830 Phase 3 Capecitabine, cisplatin, Radiotherapy (+/-)
16 Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction Completed NCT01646476 Phase 3
17 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
18 Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer Completed NCT00978549 Phase 3 docetaxel;steroid therapy
19 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296335 Phase 3 Mitomycin, doxifluridine and cisplatin;Mitomycin and doxifluridine
20 A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer Completed NCT02560974 Phase 3 Capecitabine;Oxaliplatin
21 Trial of Adjuvant Chemotherapy for Gastric Cancer Completed NCT00296322 Phase 3 cisplatin, mitomycin-C, doxifluridine
22 Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer Completed NCT00411229 Phase 3 Capecitabine;Oxaliplatin
23 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed NCT00917384 Phase 3 Placebo
24 Metastatic Gastric Cancer FFCD 03-07 Completed NCT00374036 Phase 3 ECC;FOLFIRI
25 S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer Completed NCT00182611 Phase 3 cisplatin;tegafur-gimeracil-oteracil potassium
26 A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer Completed NCT01662869 Phase 3 5-Fluoruracil;Folinic acid;Onartuzumab;Oxaliplatin;Placebo
27 Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer Completed NCT00002615 Phase 3 cisplatin;epirubicin hydrochloride;fluorouracil
28 Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer Completed NCT00020787 Phase 3 cisplatin;fluorouracil
29 Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Completed NCT00879333 Phase 3 Everolimus;Everolimus placebo;Best Supportive Care (BSC)
30 S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients Recruiting NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
31 Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Recruiting NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
32 D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma Recruiting NCT01882933 Phase 3 HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
33 Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection Recruiting NCT01534546 Phase 3 Oxaliplatin capecitabine;Oxaliplatin S-1;Oxaliplatin S-1
34 Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction Recruiting NCT02578368 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Trastuzumab;sodium folinate
35 Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer Recruiting NCT02240524 Phase 3
36 Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
37 A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer Recruiting NCT02144727 Phase 3
38 FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer Recruiting NCT02581462 Phase 2, Phase 3 FLOT alone
39 Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial Recruiting NCT01761461 Phase 3 TS-1, oxaliplatin
40 Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer Recruiting NCT03042611 Phase 3 Apatinib
41 Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer Recruiting NCT02289547 Phase 3 Capecitabine
42 Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma Recruiting NCT01711242 Phase 3 Capecitabine;Oxaliplatin
43 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Recruiting NCT02898077 Phase 3 Ramucirumab;Paclitaxel;Placebo
44 Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy Recruiting NCT03223740 Phase 3
45 Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer Recruiting NCT01917552 Phase 3 capecitabine
46 Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction Recruiting NCT01962246 Phase 2, Phase 3 Oxaliplatin; Capecitabine
47 FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) Recruiting NCT02661971 Phase 2, Phase 3 Docetaxel;Oxaliplatin;Calciumfolinat;5-Fluorouracil
48 Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction Recruiting NCT01523015 Phase 2, Phase 3
49 Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer Recruiting NCT00450203 Phase 2, Phase 3 capecitabine;cisplatin;Epirubicin;Lapatinib
50 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Active, not recruiting NCT02625610 Phase 3 Avelumab;Oxaliplatin;5-Fluorouracil;Leucovorin;Capecitabine;Oxaliplatin;5-Fluorouracil;Leucovorin;Capecitabine

Search NIH Clinical Center for Gastric Adenocarcinoma

Genetic Tests for Gastric Adenocarcinoma

Anatomical Context for Gastric Adenocarcinoma

MalaCards organs/tissues related to Gastric Adenocarcinoma:

38
Lymph Node, Liver, Bone, Lung, Eye, Skin, Colon

Publications for Gastric Adenocarcinoma

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 1092)
# Title Authors Year
1
Vimentin-positive gastric adenocarcinoma arising in a hyperplastic polyp. ( 29417386 )
2018
2
Effects of carvacrol on human fibroblast (WS-1) and gastric adenocarcinoma (AGS) cells in vitro and on Wistar rats in vivo. ( 29442269 )
2018
3
Effect of total number of harvested lymph nodes on survival outcomes after curative resection for gastric adenocarcinoma: findings from an eastern high-volume gastric cancer center. ( 29329569 )
2018
4
<i>Celastrus orbiculatus</i> extracts induce apoptosis and inhibit invasion by targeting the maspin gene in human gastric adenocarcinoma cells. ( 29387218 )
2018
5
Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance. ( 29343680 )
2018
6
Tumor of the Turkish saddle with endocrine disorders as the first manifestation of gastric adenocarcinoma. ( 29385110 )
2018
7
<i>Helicobacter pylori</i> eradication treatment and the risk of gastric adenocarcinoma in a Western population. ( 29382776 )
2018
8
Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( 29364834 )
2018
9
2,4-Di-tert-butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells. ( 29427610 )
2018
10
Cancer cell-derived von Willebrand factor enhanced metastasis of gastric adenocarcinoma. ( 29362409 )
2018
11
Effects of miR-21 on proliferation and apoptosis in human gastric adenocarcinoma cells. ( 29403555 )
2018
12
Sequential spinal and intracranial dural metastases in gastric adenocarcinoma: A case report. ( 29434454 )
2018
13
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
14
Subhyaloid hemorrhage as the first presenting sign of gastric adenocarcinoma. ( 29310953 )
2018
15
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas. ( 26567008 )
2017
16
Prognostic role of BiP/GRP78 expression as ER stress in patients with gastric adenocarcinoma. ( 28854502 )
2017
17
Gastric Adenocarcinoma with Systemic Metastasis Involving the Intraocular Choroid and Duodenum. ( 28835091 )
2017
18
Expression and prognostic significance of cyclin-dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma. ( 29344191 )
2017
19
[Increased expressions of peripheral PD-1(+) lymphocytes and CD4(+)CD25(+)FOXP3(+) T cells in gastric adenocarcinoma patients]. ( 28031121 )
2017
20
Long-term Trends in Primary Sites of Gastric Adenocarcinoma in Japan and the United States. ( 28819392 )
2017
21
MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. ( 28836853 )
2017
22
Early gastric adenocarcinoma arising within foveolar-type dysplasia in a patient with Muir-Torre variant Lynch syndrome. ( 28501935 )
2017
23
Imperatorin shows selective antitumor effects in SGC-7901 human gastric adenocarcinoma cells by inducing apoptosis, cell cycle arrest and targeting PI3K/Akt/m-TOR signalling pathway. ( 29332340 )
2017
24
An application study of low-dose computed tomography perfusion imaging for evaluation of the efficacy of neoadjuvant chemotherapy for advanced gastric adenocarcinoma. ( 28871423 )
2017
25
The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. ( 28948368 )
2017
26
Dyskeratosis congenita, bone marrow failure, and gastric adenocarcinoma: an insight into telomere biology. ( 28699608 )
2017
27
Gastric adenocarcinoma. ( 28805208 )
2017
28
Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. ( 28044374 )
2017
29
Expression and potential roles of sodium-potassium ATPase and E-cadherin in human gastric adenocarcinoma. ( 28832634 )
2017
30
CT/MRI accuracy in detecting and determining preoperative stage of gastric adenocarcinoma in Albania. ( 28947888 )
2017
31
Systemic Inflammation Response Index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection. ( 28828692 )
2017
32
Extensive Lymph Node Dissection Improves Survival among American Patients with Gastric Adenocarcinoma Treated Surgically: Analysis of the National Cancer Database. ( 29302372 )
2017
33
Analysis of survival and prognosis of 298 gastric adenocarcinoma patients with no distant metastasis. ( 29344226 )
2017
34
Massive trapezial metastasis from gastric adenocarcinoma resected and reconstructed with a vascularized scapular bone graft: A case report. ( 29390390 )
2017
35
Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. ( 28815316 )
2017
36
Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. ( 29178944 )
2017
37
Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma. ( 28035352 )
2017
38
Subacute cutaneous lupus erythematosus - paraneoplastic to gastric adenocarcinoma? ( 28421344 )
2017
39
The Nutritive Value of Organic and Conventional White Cabbage (Brassica Oleracea L. Var. Capitata) and Anti-Apoptotic Activity in Gastric Adenocarcinoma Cells of Sauerkraut Juice Produced Therof. ( 28838245 )
2017
40
Iodine Concentration in Spectral CT: Assessment of Prognostic Determinants in Patients With Gastric Adenocarcinoma. ( 28871809 )
2017
41
Clinicopathological evaluation of Sox10 expression in diffuse-type gastric adenocarcinoma. ( 27943102 )
2017
42
Detection and Significance of Human Epidermal Growth Factor Receptor 2 Expression in Gastric Adenocarcinoma. ( 28900323 )
2017
43
An unusual primary malignant tumor of the stomach: Fetal gut-like Gastric adenocarcinoma with "blastoma"-like component. ( 28315695 )
2017
44
Gastrin activates autophagy and increases migration and survival of gastric adenocarcinoma cells. ( 28109268 )
2017
45
Tumoral FOXP3 expression is associated with favorable clinicopathological variables and good prognosis in gastric adenocarcinoma; the tumor suppressor function of tumoral FOXP3 is related with the P21 expression in gastric adenocarcinoma. ( 28882702 )
2017
46
Effects of natural phenolic compound carvacrol on the human gastric adenocarcinoma (AGS) cells in vitro. ( 28244942 )
2017
47
Overexpression of HER-2 Protein is a High-Risk Factor for Patients with Surgically-Resected Stage T3 Gastric Adenocarcinoma. ( 28164509 )
2017
48
Expression and Significance of Cyclophilin J in Primary Gastric Adenocarcinoma. ( 28739742 )
2017
49
CDH17 Is a More Sensitive Marker for Gastric Adenocarcinoma Than CK20 and CDX2. ( 28029907 )
2017
50
Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. ( 28736638 )
2017

Variations for Gastric Adenocarcinoma

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6 (show top 50) (show all 101)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh38 Chromosome 10, 87933148: 87933148
2 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
3 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
4 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
5 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
6 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
7 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
8 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
9 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
10 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
11 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
12 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
13 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
15 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
16 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
17 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
18 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
19 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
20 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
21 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
22 FGFR2 NM_022970.3(FGFR2): c.755C> G (p.Ser252Trp) single nucleotide variant Pathogenic/Likely pathogenic rs79184941 GRCh37 Chromosome 10, 123279677: 123279677
23 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
24 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
25 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
26 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
27 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
28 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
29 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
30 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
31 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
32 ERBB2 NM_001005862.2(ERBB2): c.2236G> A (p.Gly746Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28933369 GRCh37 Chromosome 17, 37880997: 37880997
33 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
34 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
35 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
36 RAF1 NM_002880.3(RAF1): c.770C> T (p.Ser257Leu) single nucleotide variant Pathogenic rs80338796 GRCh37 Chromosome 3, 12645699: 12645699
37 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
38 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
39 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
40 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
41 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
42 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
43 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
44 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097
45 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
46 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104
47 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
48 SMAD4 NM_005359.5(SMAD4): c.1081C> G (p.Arg361Gly) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
49 SMAD4 NM_005359.5(SMAD4): c.1082G> A (p.Arg361His) single nucleotide variant Pathogenic/Likely pathogenic rs377767347 GRCh37 Chromosome 18, 48591919: 48591919
50 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh38 Chromosome 3, 179210192: 179210192

Cosmic variations for Gastric Adenocarcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43583 TP53 skin,eye,carcinoma,NS c.425C>T p.P142L 3
2 COSM45444 TP53 skin,eye,carcinoma,NS c.587G>T p.R196L 3
3 COSM44126 TP53 skin,eye,carcinoma,NS c.507G>A p.M169I 3
4 COSM144245 PTCH1 skin,eye,carcinoma,NS c.1585A>T p.K529* 3
5 COSM498 HRAS skin,eye,carcinoma,NS c.182A>T p.Q61L 3

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain C1orf88 Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain SPFH1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain ST5 Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss KIAA0179 Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma

Expression for Gastric Adenocarcinoma

Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for Gastric Adenocarcinoma

Pathways related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.32 CDH1 CTNNB1 ERBB2 HRAS MAP2K2 RAF1
2
Show member pathways
13.02 CTNNB1 HRAS MAP2K2 MYC PTGS2 RAF1
3
Show member pathways
12.97 CDH1 CTNNB1 ERBB2 FHIT HRAS MAP2K2
4
Show member pathways
12.94 CTNNB1 ERBB2 HRAS MAP2K2 PTGS2 RAF1
5
Show member pathways
12.77 CDH1 CTNNB1 HRAS MAP2K2 RAF1
6
Show member pathways
12.7 CDH1 CTNNB1 ERBB2 HRAS MAP2K2 PTGS2
7
Show member pathways
12.68 CDX2 CTNNB1 HRAS MAP2K2 RAF1
8
Show member pathways
12.61 CTNNB1 HRAS MAP2K2 MYC PTGS2 RAF1
9 12.54 ERBB2 HRAS MAP2K2 MYC PTGS2 RAF1
10
Show member pathways
12.53 ERBB2 HRAS MAP2K2 MYC RAF1
11 12.53 CDH1 CTNNB1 ERBB2 HRAS MAP2K2 MLH1
12
Show member pathways
12.52 ERBB2 HRAS MAP2K2 MYC RAF1
13 12.46 CDH1 CTNNB1 GAST MYC PTGS2
14
Show member pathways
12.44 CTNNB1 HRAS MAP2K2 PTGS2 RAF1
15
Show member pathways
12.43 HRAS MAP2K2 MYC RAF1
16
Show member pathways
12.41 HRAS MAP2K2 MYC RAF1
17
Show member pathways
12.4 CTNNB1 HRAS MAP2K2 RAF1
18
Show member pathways
12.4 CCKBR GAST HRAS MAP2K2 RAF1
19
Show member pathways
12.37 CTNNB1 HRAS MAP2K2 MYC RAF1
20
Show member pathways
12.31 CDH1 CTNNB1 HRAS RAF1
21
Show member pathways
12.3 ERBB2 HRAS MAP2K2 PTGS2 RAF1 TFF1
22
Show member pathways
12.29 CDH1 CTNNB1 ERBB2 HRAS MAP2K2 MYC
23
Show member pathways
12.28 CDH1 CDX2 CTNNB1 ERBB2 HRAS MAP2K2
24
Show member pathways
12.27 ERBB2 HRAS MAP2K2 MYC RAF1
25 12.26 CTNNB1 ERBB2 HRAS MAP2K2 MYC RAF1
26 12.23 ERBB2 HRAS MAP2K2 RAF1
27 12.22 HRAS MAP2K2 MYC RAF1
28 12.2 AFP CDH1 CTNNB1 MYC
29
Show member pathways
12.19 HRAS MAP2K2 MYC RAF1
30
Show member pathways
12.19 ERBB2 HRAS MAP2K2 MYC RAF1
31
Show member pathways
12.18 ERBB2 HRAS MAP2K2 MYC RAF1
32
Show member pathways
12.16 CTNNB1 ERBB2 HRAS RAF1
33 12.15 CTNNB1 HRAS MAP2K2 RAF1
34 12.13 CDH1 HRAS MAP2K2 RAF1
35
Show member pathways
12.12 HRAS MAP2K2 MYC RAF1
36 12.12 CTNNB1 HRAS MAP2K2 MYC RAF1
37 12.1 CDH1 CTNNB1 MAP2K2 MLH1 MYC PTGS2
38 12.06 CDH1 CEACAM5 CTNNB1 TFF1
39 12.06 CDH1 CTNNB1 HRAS MAP2K2 RAF1
40 12.02 CTNNB1 ERBB2 HRAS MYC
41
Show member pathways
12.01 HRAS MAP2K2 MYC RAF1
42 12 CTNNB1 HRAS MAP2K2 MYC RAF1
43 11.95 CTNNB1 HRAS MAP2K2 MYC RAF1
44
Show member pathways
11.93 HRAS MAP2K2 MYC RAF1
45 11.87 HRAS MAP2K2 RAF1
46
Show member pathways
11.84 HRAS MAP2K2 RAF1
47 11.81 CDH1 CTNNB1 MYC
48 11.78 ERBB2 HRAS MAP2K2 RAF1
49 11.77 CDH1 CTNNB1 ERBB2
50 11.75 CTNNB1 ERBB2 MYC RAF1

GO Terms for Gastric Adenocarcinoma

Cellular components related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.17 CDH1 CHGA CTNNB1 ERBB2 HRAS MAP2K2
2 catenin complex GO:0016342 9.16 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.96 CDH1 CTNNB1

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.83 CTNNB1 HRAS PTGS2 RAF1 TFF1
2 positive regulation of cell proliferation GO:0008284 9.8 CCKBR CDX2 CTNNB1 HRAS MYC PTGS2
3 MAPK cascade GO:0000165 9.65 ERBB2 HRAS MAP2K2 MYC RAF1
4 positive regulation of epithelial cell proliferation GO:0050679 9.58 ERBB2 HRAS MYC
5 ovulation GO:0030728 9.49 MYC PTGS2
6 entry of bacterium into host cell GO:0035635 9.48 CDH1 CTNNB1
7 negative regulation of blood vessel diameter GO:0097756 9.46 CHGA PTGS2
8 wound healing GO:0042060 9.46 ERBB2 RAF1 S100A8 TFF1
9 cellular response to indole-3-methanol GO:0071681 9.37 CDH1 CTNNB1
10 negative regulation of gene expression GO:0010629 9.35 CTNNB1 HRAS MAP2K2 MYC ROS1
11 cell proliferation GO:0008283 9.17 CCKBR CTNNB1 ERBB2 HRAS MYC RAF1

Molecular functions related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 CTNNB1 ERBB2 ROS1
2 nucleotide binding GO:0000166 9.02 ERBB2 FHIT HRAS MAP2K2 RAF1
3 protein binding GO:0005515 10.09 AFP CCKBR CDH1 CTNNB1 ERBB2 FHIT

Sources for Gastric Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....